Oral selective estrogen receptor degraders, or oral SERDs, are reshaping treatment for estrogen receptor-positive, HER2-negative breast cancer, especially when tumors acquire ESR1 mutations that make older endocrine therapies less effective. Unlike aromatase inhibitors, which reduce estrogen production, or tamoxifen, which blocks the estrogen receptor without degrading it, oral SERDs bind the receptor and promote its breakdown inside the cancer cell.
Endocrine therapy works by interrupting estrogen signaling
Most estrogen receptor-positive breast cancers depend on estrogen receptor signaling to support tumor growth. Endocrine therapy exploits that dependence, but different drug classes interrupt the pathway at different points.
Aromatase inhibitors such as letrozole, anastrozole, and exemestane reduce estrogen production by blocking aromatase, the enzyme that converts androgens into estrogens. Tamoxifen is a selective estrogen receptor modulator, or SERM, that binds the estrogen receptor and changes how the receptor signals in different tissues. Fulvestrant is an injectable SERD that binds the estrogen receptor and promotes receptor degradation.
Oral SERDs use the same broad degradation strategy as fulvestrant but are designed to be taken by mouth, avoiding repeated intramuscular injections and allowing newer compounds to achieve pharmacologic profiles that were difficult to obtain with first-generation injectable SERDs.
Fulvestrant proved receptor degradation could work, but delivery was a limitation
Fulvestrant established selective estrogen receptor degradation as a clinically useful strategy. It binds estrogen receptor alpha, blocks receptor signaling, and accelerates receptor turnover. Its major practical limitation is formulation: fulvestrant is given as large-volume intramuscular injections, typically into the buttocks.
That delivery route does not make fulvestrant ineffective, but it created a strong incentive to develop orally bioavailable degraders. Oral drugs can be easier to administer chronically and may allow more consistent systemic exposure, although convenience alone does not guarantee superior efficacy.
ESR1 mutations explain why oral SERDs have become especially important
ESR1 encodes estrogen receptor alpha. During treatment with aromatase inhibitors, some breast cancers acquire mutations in the receptor’s ligand-binding domain. These mutations can keep the receptor active even when estrogen levels are very low, creating a mechanism of resistance to estrogen deprivation.
That biology helps explain why oral SERDs have shown their most consistent benefit in ESR1-mutated tumors. Rather than relying on estrogen deprivation alone, SERDs attack the receptor itself.
Our ESR1 mutations explainer covers how these mutations emerge and why they matter clinically.
Elacestrant was the first oral SERD approved for ESR1-mutated breast cancer
FDA approved elacestrant, sold as Orserdu, in January 2023 for postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on at least one line of endocrine therapy.
The approval was based on EMERALD, an open-label phase 3 trial that randomized 478 patients to elacestrant or standard endocrine therapy, which could include fulvestrant or an aromatase inhibitor. All patients had previously received a CDK4/6 inhibitor.
In the ESR1-mutated subgroup, elacestrant reduced the risk of progression or death by 45% compared with standard endocrine therapy, with a hazard ratio of 0.55 (95% confidence interval, 0.39 to 0.77; P=0.0005). In the overall trial population, the hazard ratio was 0.70.
FDA ultimately restricted the indication to ESR1-mutated disease because the overall progression-free survival benefit was driven primarily by that subgroup.
Imlunestrant reinforced the biomarker-driven pattern
Imlunestrant, marketed as Inluriyo, was approved in September 2025 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy.
In EMBER-3, 874 patients were randomized to imlunestrant, standard endocrine therapy, or imlunestrant plus abemaciclib. Among 256 patients with ESR1 mutations, median progression-free survival was 5.5 months with imlunestrant versus 3.8 months with standard therapy. The restricted mean progression-free survival difference at 19.4 months was 2.6 months in favor of imlunestrant.
By contrast, imlunestrant did not significantly improve progression-free survival versus standard endocrine therapy in the overall population regardless of ESR1 status. That pattern again points to ESR1 mutation as a key biomarker for selecting patients most likely to benefit from oral SERD monotherapy.
The treatment landscape has already moved beyond monotherapy. Our Inluriyo plus Verzenio approval article explains the newer combination strategy with the CDK4/6 inhibitor abemaciclib.
Camizestrant shows a different way to use an oral SERD
Camizestrant, marketed as Etcamah, illustrates a different treatment strategy. FDA granted accelerated approval in September 2026 for camizestrant in combination with a CDK4/6 inhibitor when an ESR1 mutation is detected during first-line aromatase inhibitor plus CDK4/6 therapy, before radiographic disease progression.
That approach comes from SERENA-6, in which patients were monitored for emerging ESR1 mutations in circulating tumor DNA. Patients whose ESR1 mutation became detectable were randomized to switch the endocrine component from an aromatase inhibitor to camizestrant while continuing the same CDK4/6 inhibitor, or to remain on the aromatase inhibitor combination.
With extended follow-up, median progression-free survival was 16.8 months with camizestrant plus a CDK4/6 inhibitor versus 9.2 months with continued aromatase inhibitor plus CDK4/6 therapy, with a hazard ratio of 0.45.
Our camizestrant approval explainer covers that treatment-switch strategy in detail.
Not every oral estrogen receptor degrader is technically a SERD
The terminology can become confusing as newer drugs reach the clinic. Vepdegestrant, approved by FDA in May 2026 for ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer, is an oral estrogen receptor degrader but is not a conventional SERD.
Vepdegestrant is a heterobifunctional protein degrader, often described as a PROTAC-style molecule. It recruits the cell’s protein-disposal machinery to target the estrogen receptor for degradation. The clinical goal overlaps with SERDs, but the molecular mechanism is different.
That distinction matters because “oral estrogen receptor degrader” is becoming a broader category than “oral SERD.”
Oral SERDs do not make older endocrine therapies obsolete
Aromatase inhibitors remain foundational first-line endocrine therapy in many patients, particularly before ESR1-mediated resistance develops. Tamoxifen remains important in several settings, especially in earlier-stage disease and in patients for whom aromatase inhibitors are not appropriate. Fulvestrant also remains a useful option in selected advanced breast cancer settings and continues to serve as a comparator in modern trials.
The advantage of oral SERDs is therefore not that older endocrine therapies have stopped working. It is that oral SERDs provide another way to suppress estrogen receptor signaling after tumors evolve mechanisms that make estrogen deprivation or older receptor-directed approaches less effective.
Safety profiles differ across the class
Oral administration does not mean these drugs have identical safety profiles. In EMERALD, nausea occurred more often with elacestrant than with standard endocrine therapy, and dyslipidemia was also reported. Imlunestrant has its own prescribing precautions, including embryo-fetal toxicity, while combination therapy with abemaciclib adds the toxicities associated with CDK4/6 inhibition.
Drug choice therefore depends on more than mechanism. Prior therapy, ESR1 mutation status, comorbidities, treatment setting, combination partners, and individual adverse-effect risk all matter.
What the evidence cannot yet answer
Most oral SERD evidence currently comes from advanced or metastatic breast cancer, and many of the pivotal trials were open-label. Several were sponsored by the companies developing the drugs, including Stemline or Menarini for elacestrant, Eli Lilly for imlunestrant, and AstraZeneca for camizestrant.
Cross-trial comparisons are also unreliable because eligibility criteria, prior CDK4/6 exposure, mutation testing, comparator therapies, and timing of treatment differ substantially among studies.
A 2026 meta-analysis of six randomized trials found that oral SERDs improved progression-free survival overall, with the strongest effect in ESR1-mutated tumors. However, another 2026 meta-analysis using a different trial set found no statistically significant progression-free survival advantage in the overall population while still finding a clear advantage in ESR1-mutated disease. The consistent signal across these analyses is therefore the biomarker-defined subgroup rather than a universal class benefit for every ER-positive tumor.
The biggest change is that endocrine therapy is becoming mutation-guided
Older endocrine therapy was largely chosen according to receptor status, menopausal status, prior treatment, and disease setting. Oral SERDs add another layer: real-time tumor evolution.
As circulating tumor DNA testing becomes more common, clinicians can increasingly detect ESR1 mutations as they emerge and use that information to change endocrine strategy. That makes oral SERDs part of a broader shift from treating ER-positive breast cancer as one category toward treating specific resistance mechanisms as they appear.
References
- Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246-3256. DOI: 10.1200/JCO.22.00338.
- Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025;392:1189-1202. DOI: 10.1056/NEJMoa2410858.